A decade ago, kratom advocates fought a surprisingly successful campaign against a proposed Drug Enforcement Administration ban that claimed the obscure Southeast Asian plant posed “an imminent hazard to public safety.”
They won bipartisan allies from Bernie Sanders to Rand Paul, and helped create a billion-dollar industry out of kratom, which has pain-relieving effects they said could help fight the opioid epidemic as a far safer, natural alternative to pills.
Now, many of those same pro-kratom activists are calling for a ban on products containing concentrates of one of kratom’s active components: 7-hydroxymitragynine, or 7-OH, an ultra-potent extract with opioid-like effects. And it’s causing major friction amongst consumers, sellers, and advocates of both substances.
“This is a chemically manipulated, full-blown opioid that is now in the marketplace,” claims Mac Haddow, the senior public policy fellow at the American Kratom Association, a kratom industry lobby group. “They masquerade as kratom products.”
The proliferation of 7-OH in gummies, capsules, and shots with brand names like Magic 7OH, 7 O’Heaven, and Pure OHMS across thousands of gas stations and corner stores over the past few years has caused increasing consternation. Consumers of 7-OH have spoken of its excruciating withdrawal symptoms, and there have been reports of polydrug overdoses involving 7-OH and other substances. Some are now entering rehab to overcome their dependency, while others are self-detoxing based on advice from Redditors.
The kratom community fears that 7-OH’s bad reputation could drag the entire kratom industry into a regulatory quagmire. But the 7-OH industry has organized against the potential prohibition, claiming 7-OH is kratom, despite only appearing in trace amounts within the leaves of the kratom plant, and that its benefits as an analgesic outweigh its potential harms.
Anti-7-OH directives from the federal government have exacerbated tensions between the two sides.
Last July, US Health and Human Services secretary Robert F. Kennedy Jr. described the 7-OH industry as “sinister” at a press conference where FDA commissioner Marty Makary called for the DEA to categorize the drug as Schedule I—the most restrictive class of banned substances. Speaking from the Oval Office on May 11, President Donald Trump publicly endorsed “natural 7-OH,” in confusing remarks which appeared to refer to kratom. On top of all that, it appears that both RFK Jr. and Department of Homeland Security secretary Markwayne Mullin—who is also pushing for a 7-OH crackdown—have strong ties to a kratom lobbyist (and convicted criminal) behind a notorious kratom drinks company.
Proponents of 7-OH see the substance and the plant it’s derived from as inexorably linked. In April 2025 testimony to Colorado legislators debating how to regulate kratom and 7-OH, Michele Ross, the chief scientific adviser to the 7-OH advocacy group 7-HOPE Alliance, wrote, “To say 7-OH is not kratom is to say caffeine is not coffee or THC is not cannabis. It simply does not make sense.”
But as opposed to coffee, cannabis, and kratom—which have been consumed for centuries if not thousands of years—7-OH does not have a long history of human use. It’s only been on the market for a few years.
Many of the products that are labeled 7-OH contain little-understood compounds with unknown biological effects in animals or humans, says Chris McCurdy, a leading kratom researcher and director of the University of Florida’s translational drug development core. “So, these products, while represented as ‘clean’ are anything but.”
Meanwhile, a dozen states, from California to Vermont, according to reports, have already moved ahead of federal scheduling with their own 7-OH bans. Seven of those states have also banned kratom, although Rhode Island recently overturned its prohibition.
![Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.
The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.
While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.
And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:
“This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.” So that’s somewhat comforting. On the other hand, according to NBC: “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.” NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads: “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly” At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch? #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.
The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.
While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.
And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:
“This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.” So that’s somewhat comforting. On the other hand, according to NBC: “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.” NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads: “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly” At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch? #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine](https://gizmodo.com/app/uploads/2026/05/Screenshot-2026-05-13-at-8.02.01 PM.jpg)